Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

Type 2 diabetes is a risk factor for developing chronic kidney disease. The main pharmaceutical ingredient in Ozempic is semaglutide, a peptide engineered to mimic the GLP-1 hormone in our bodies.

Ozempic becomes the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease Mario Tama/Getty The Food and Drug Administration has approved Ozempic to reduce the ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

about a third of adults with diabetes also have chronic kidney disease, according to the US Centers for Disease Control and Prevention The clinical trial tested the efficacy of Ozempic when added ...